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Abstract
β-escin is a mixture of triterpene saponins isolated from the horse chestnut seeds (Aescu-
lus hippocastanum L.). The anti-edematous, anti-inflammatory and venotonic properties of
β-escin have been the most extensively clinically investigated effects of this plant-based
drug and randomized controlled trials have proved the efficacy of β-escin for the treatment
of chronic venous insufficiency. However, despite the clinical recognition of the drug its
pharmacological mechanism of action still remains largely elusive. To determine the cellu-
lar and molecular basis for the therapeutic effectiveness of β-escin we performed discovery
and targeted proteomic analyses and in vitro evaluation of cellular and molecular responses
in human endothelial cells under inflammatory conditions. Our results demonstrate that in
endothelial cells β-escin potently induces cholesterol synthesis which is rapidly followed
with marked fall in actin cytoskeleton integrity. The concomitant changes in cell functioning
result in a significantly diminished responses to TNF-α stimulation. These include reduced
migration, alleviated endothelial monolayer permeability, and inhibition of NFκB signal
transduction leading to down-expression of TNF-α—induced effector proteins. Moreover,
the study provides evidence for novel therapeutic potential of β-escin beyond the current
vascular indications.
Introduction
β-escin is a mixture of triterpene saponins isolated from horse chestnut seeds (Aesculus hippo-
castanum, L.). Although ethnopharmacological research provides evidence for its broad use to
treat numerous diverse disorders, including bladder diseases, cough, diarrhea, dysmenorrhea
and tinnitus [1], its current use is restrictedmainly to venotonic and venoprotective indica-
tions. anti-inflammatory and anti-edematous properties Indeed, randomized controlled trials
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[2, 3].
The clinical reports on vascular efficacy of β-escin draw particular attention to improved
microcirculation, reduced vascular permeability, increased venous tone and venous return, all
which lead to edema reduction (reviewed in [4]). It has been suggested that the observed effects
result from protection of endothelial cells from hypoxia and inflammatory stimuli provided by
the drug [5]. In fact, as shown in preclinical studies, β-escin conserves ATP during oxygen
shortage [6], decreases histamine response [5] and cytokine release [7], attenuates serotonin-
induced capillary hyperpermeability [8], suppresses extravasation and leukocytemigration [9]
and preserves endothelial cell morphology [7]. Worth mentioning are also data indicating anti-
oxidant potential of β-escin [10, 11] and its inhibitory effect on hyaluronidase, an enzyme
implicated in the pathogenesis of CVI [12]. In more recent studies inflammation attenuating
properties of β-escin has been linked to its modulatory effect on the TNF-α-mediated inflam-
matory pathways [13].
Despite the therapeutic significance of β-escin and the popularity of the drug which in the
United States and Europe remains one of the best-selling herbal extracts accounting for 226
million U.S. dollar-market in 2014 (IMS Kilochem), its exact mechanism of action remains
unknown [14]. In the present study we applied a broad experimental approach, including
global discovery-type and targeted proteomic methods in conjunction with cellular biology
tools to identify novel pathways underlying the protective effects of β-escin in human endothe-
lial cells under inflammatory conditions. The obtained results indicate that the vascular anti-
inflammatorymechanism of β-escin involves disturbances in cholesterol homeostasis leading
to cytoskeletal perturbations followed by decreasedNFκB activation.
Methods
Cell culture
Human Umbilical Vein Endothelial Cells (HUVEC, sex unknown, Lonza) were cultured in the
EBM-2 (Lonza) supplemented with endothelial growth supplement mix (EGM-2 SingleQuot
Kit Supplements and Growth Factors, Lonza) under standard cell culture condition (37°C, 5%
CO2). Cells were harvested using Accutase (PAA Laboratories). All described experiments
were performedwith cells of passage four from at least three donors. Unless stated otherwise,
the cells were treated for 24 h with DMSO-solubilized β-escin (Nobilus Ent) with or without
stimulation of recombinant human TNF-α (rhTNF-α, 10 ng/ml, R&D Systems) for the last 6 h
of the experiment. As DMSO concentration in cell culture media did not exceed 0.015%, i.e. its
effect of HUVECwas negligible [15], DMSO controls were not included in the experimental
protocols.
Cell viability and proliferation assays
To reliably evaluate viability and proliferative response of cells we used two complementary
methods. DNA synthesis in replicating cells was assessed with the BrdU Cell Proliferation
Assay (Calbiochem,QIA58), while the ability of intracellular esterases to convert calcein AM, a
nonfluorescent substrate into calcein, a fluorescent product was used to evaluate the cell num-
ber (Ultrasensitive Cell Proliferation Assay, Calbiochem,QIA128). Briefly, 7 x103 cells/100 μl/
well seeded into a 96-well culture dish were allowed to attach overnight prior to the treatment.
BrdU was incubated with cells for 24 h, which was followed by a fixative/denaturing step, 1 h
anti-BrdU antibody (1∶100) and subsequent 30 min horseradish peroxidase-conjugated goat
anti-mouse staining. Incorporated BrdU was detected spectrophotometrically at dual wave-
lengths of 450–540 nm. Accumulation of fluorescent calcein was determined 1.5 h after
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supplementing cell culture with calcein AM using a fluorescent plate reader with 485 nm exci-
tation and 520 nm emission filters. In both assays the total incubation time with β-escin was
48 h.
Cell migration assay
The rate of cell migration was measured with the BD BioCoat™ Angiogenesis System: Endothe-
lial Cell Migration (BD Biosciences, cat. no 354144) strictly according to the manufacturer’s
instructions. Briefly, confluent HUVECwere serum starved for 4 h and seeded on migration
inserts (1x105 cells/250 μμl). After 22-hour treatment with β-escin with or without 6-hour
TNF-α stimulation, the cells on inserts were stained with Calcein AM Fluorescent Dye solution
(BD Biosciences) and fluorescence of migrated cells was read directly in a fluorescence plate
reader with 485 nm excitation and 520 nm emission filters (Perkin Elmer).
Vascular permeability assay
The In Vitro Vascular Permeability Assay Kit (Chemicon) was used to determineHUVEC
monolayer permeability. All steps of the procedure were performed according to the manufac-
turer’s instructions. Briefly, 1.8 x 105 cells were plated on the insert, cultured until confluency,
and treated with β-escin for 24 h. TNF- α was used as permeability factor for the last 6 h of the
cell culture. To evaluate the permeability treatment fluorescein isothiocyanate-conjugated dex-
tran was added to the upper chambers for 20 minutes, then the medium from the lower cham-
bers was harvested and its florescence intensity measured with 485 nm excitation and 535 nm
emission filters.
Cytoskeletal staining
For cytoskeletal staining, HUVECwere washed in PBS, fixed with 3% paraformaldehyde and
permeabilizedwith 0.05% Triton X-100. Polymerized, filamentous actin (F-actin) was visual-
ized by staining with tetramethylrhodamine B isothiocyanate (TRITC)-phalloidin (Sigma-
Aldrich). For actin and tubulin co-staining, HUVECwere washed, fixed and permeabilized, as
described above. Following incubation with TRITC-phalloidin, primarymonoclonal anti-α-
tubulin antibody (Sigma-Aldrich) and fluorochrome-conjugated secondary antibody (Alexa
Fluor 488) were used. DNA dye DRAQ5 was used to localize the nucleus. Coverslips were
mounted using fluorescencemounting medium (DakoCytomation). Samples were analyzed
using confocal microscopy (Axiovert 100M, Zeiss) with the LSM 510 META application.
Evaluation of globullar/fibrillar actin ratio
Determination of actin monomers (globular actin, G-actin) and actin filaments (polymerized,
filamentous actin, F-actin) ratio was carried out using the G-actin/F-actin In Vivo Assay kit
(Cytoskeleton) strictly according to the manufacturer’s protocol. Briefly, 1x106 cells were lysed,
homogenized and centrifuged at 400 g for 5 minutes. The obtained supernatant containing
total cellular actin was centrifuged at 100,000 x g for 1 h at 37°C to separate F-actin (pellet)
from soluble G-actin (supernatant). F-actin pellets were resuspended in ice cold dH2O contain-
ing 10 μM cytochalasinD to the same volume as the G-actin supernatant. Equal volumes of
samples were analyzed by Western blotting with the anti-actin antibody (Sigma Aldrich, cat.
no A3854). The ratio of F-actin to G-actin in each sample was calculated following the densi-
tometry analysis performedwith the use of ImageJ software (http://imagej.nih.gov).
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Cholesterol quantification
Total cholesterol concentration was measured using the fluorometric Amplex Red Cholesterol
assay (Invitrogen). Briefly, 6 x 106 cells were lysed in 400 μl PBS by three consecutive freeze/
thaw cycles at -80°C and centrifuged at 14,000 x g for 10 minutes in 4°C. Reactions containing
150 μM Amplex1 Red reagent, 1 U/ml HRP, 1 U/ml cholesterol oxidase, 0,1 μM cholesterol
esterase and 50 μl of cell lysates or known amount of cholesterol for standard curve, were incu-
bated at 37°C for 30 minutes. Fluorescence was measured with a fluorescencemicroplate reader
(excitation: 560 nm; emission: 590 nm). Each assay run included no-cholesterol negative con-
trol and 10 μMH2O2 positive control, as per manufacturer’s instructions. Obtained values
were normalized to total cellular protein concentration measured by the Lowrymethod
(Biorad).
Transcription factors quantification
To detect and quantify NFκB p50 and p65 transcription factors activation we used NFκB p50
and NFκB p65 ELISA Kits with Nuclear Extraction Kits (Affymetrix) following the manufac-
turer’s instructions. For each experimental sample, nuclear extracts were obtained from 6
x106 cells grown to confluence. Protein concentration was measured by the Lowrymethod
(Biorad).
Global proteomic analysis and multiple reaction monitoring (MRM)
analysis of targeted proteins
Details of the materials and methods are presented in the Supporting Information (S1 Meth-
ods). Briefly, the global discovery-typeproteomic analysis was carried out using the Isobaric
Tags for Relative and Absolute Quantitation (iTRAQ) method which enables the identification
and relative quantitation of all detectable proteins present in the samples.[16] Proteins were
identifiedwith Mascot and differentially expressed proteins were assessed using the Diffprot
and MScan software tools with estimation of statistical significance [17]. A minimum number
of two peptides with a false-discovery rate<1% were used for confident identification of a pro-
tein in the iTRAQ experiment. Subsequently, 32 proteins were selected to be subjected to
MRM analysis for accurate targeted verification of iTRAQ results and further analysis of larger
samples sets. Each protein was represented by one to three unique peptides. For 23 selected
proteins, stable isotope-labeled standard (SIS) peptides were used for increased accuracy and
stable-isotope-dilution-MRM(SID-MRM) was performed, and nine proteins of the cholesterol
biosynthesis pathway were assessed by MRMwithout the use of SIS peptides (MRM) but with
normalization to beta and gamma actin peptides.
Statistics
All data are presented as mean ± SEM.When error bars do not appear in the figures, errors are
within the size of the symbol used there. All statistical analyses were carried out with GraphPad
Prism 5.04 software. Data were analyzed by one-way analyses of variance (ANOVA) followed
by the post hoc Tukey multiple range test, unless indicated otherwise.Differences between
groups were rated significant at a probability error (p) of< 0.05. For MRM results t- test with
Benjamini -Hochberg correctionwas used to asses significant differences between treatment
groups (p -values<0.05).
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Pathway analysis
For canonical pathways and network analyses proteins with significant alterations in quantity
were submitted to Ingenuity Pathway Analysis (Ingenuity Systems, RedwoodCity, CA; http://
www.ingenuity.com).
Results
Effect of β-escin on endothelial cell viability and proliferation
Structurally β-escin belongs to saponins which are known for their membrane-permeabilising
properties [18]. Their lytic action on erythrocytemembranes is one of the best known features
shared by all molecules of this chemical class. In order to evaluate the effect of β-escin on
HUVEC viability and proliferation we measured the number of viable cells and the BrdU
incorporation rate. As shown in Fig 1A, β-escin induced toxicity assessed following 48 h treat-
ment was observed in concentrations above 4 μM and the effect was not significantly influ-
enced with TNF-α. β-escin influence on HUVEC proliferation rate was quantified after 48 h of
culture, became statistically significant at the 3 μM for cells treated with β-escin and TNF-α
and at the 4 μμM concentration for cells cultured with β-escin without TNF-α (Fig 1B).
Fig 1. The effects of β-escin on quiescent and TNF-α-treated vascular endothelial cells: viability (Panel A), proliferation (Panel B), migration
(Panel C) and permeability (Panel D) of HUVEC presented as a percentage of fluorescence (Panels A, C and D) or absorbance readouts (Panel B)
in the control, untreated cells. Abbreviations: C -untreated cells; TNF—TNF-α-treated cells; E—β-escin-treated cells. Results are expressed as mean
±SEM of three experiments with cells obtained from at least three donors. Data were analyzed by one-way analyses of variance (ANOVA) followed by the
post hoc Tukey multiple range test. *p < 0.05; **p < 0.01; ***p < 0.001
doi:10.1371/journal.pone.0164365.g001
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Effect of β-escin on endothelial cell migration
The ability of a cell to migrate is essential in numerous vascular responses, including vascular
inflammation and angiogenesis. β-escin induced decline in migration of both quiescent and
TNF-α stimulated cells reached statistical significance at the 2 μM concentration (Fig 1C).
Effect of β-escin on endothelial layer integrity
The integrity of the endothelial cell monolayer is one of the key conditions necessary to protect
vascular homeostasis. As demonstrated in Fig 1D, β-escin protected the endothelial layer
against TNF-α-induced permeability. The observed effect was statistically significant already at
the 1 μM concentration of β-escin.
Cholesterol content
β-escin-dependent loss of membrane cholesterol has been previously solidly confirmed [19].
Results presented in Fig 2 present a statistically significant rise in total cellular cholesterol con-
tent following 24 h of β-escin treatment.
β-escin disrupts the actin cytoskeleton
Well-established evidence links the integrity of the actin cytoskeleton with normal cellular
responses. Moreover, it has been documented that the organization of cell actin is cholesterol-
Fig 2. The change of total intracellular intracellular cholesterol content in HUVEC following treatment with
3 μM β-escin. Abbreviations: C—untreated HUVEC; E—β-escin treated cells. The results are expressed as the
mean ±SEM of three independent experiments with cells obtained from at least six donors. Data were analyzed by
one-way analyses of variance (ANOVA) followed by the post hoc Tukey multiple range test. *p < 0.05
doi:10.1371/journal.pone.0164365.g002
The Molecular Basis for Therapeutic Effectiveness of β-Escin
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sensitive. Disturbed cholesterol homeostasis and reducedmigratory response of β-escin treated
endothelial cells prompted us to investigate its effect on the actin cytoskeleton in HUVEC.
As demonstrated with two different techniques, β-escin induced depolymerization of actin
filaments. Staining of fibrillar actin with phalloidin revealedmorphological changes and actin
cytoskeleton remodeling, as demonstrated by confocal microscopy (Fig 3). In addition, the
assessment of fibrillar and globular actin fractions demonstrated an increase in the G-actin / F-
actin ratio from 1.8 in control to 4.2 in β-escin treated samples (Fig 4). Neither TNF-α nor β-
escin, alone or in the combined treatment, had a statistically significant effect on the total cell
actin content as shown by MRM analysis of both beta and gamma actin (data not shown). No
effect of β-escin on the total actin content suggests that the modifications of actin cytoskeleton
are not related to altered actin synthesis.
Differential proteome analysis of the β-escin-treated endothelial cells
using iTRAQ
Results of the aforementioned functional analyses of endothelial cells cultured in the presence
of β-escin prompted us to perform a discovery-typeproteomic study using the iTRAQ tech-
nique. We applied this method to discover proteins involved in β-escin induced cellular
responses and to elucidate the anti-inflammatorymechanisms of β-escin action in more detail.
Although at a low concentration (1 μM) β-escin did not induce significant changes in the
protein profile (data not shown), at the 3 μM concentration it strongly affected the protein
expression pattern (S1 Fig and Table A in S1 Methods). Importantly, we also revealed 75
Fig 3. HUVEC actin cytoskeleton remodeling following treatment with increasing concentrations of β-escin. Upper panel: actin staining of: A—
control cells; B, C, D—β-escin-treated cells (1, 2 and 3 μM, respectively). Lower panel (A’, B’, C’, D’): magnification of selected fragments. Similar results
were observed in three independent experiments with cells obtained from three donors.
doi:10.1371/journal.pone.0164365.g003
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differentially expressed proteins in β-escin and TNF-α treated cells as compared to TNF-α
stimulated cells (S1 Fig and Table B in S1 Methods).
To assemble and evaluate protein–protein associations and to identify functional protein
linkages we next analyzed the differentially expressed proteins using IPA. The ten canonical
pathways most significantlymodulated with β-escin treatment, presented in Fig 5, shed more
light on the cellular and biochemical data obtained in the study. The findings emphasize the
importance of the increased cholesterol synthesis in β-escin-treated endothelial cells, as pre-
sented in more detail in S2 Fig.
Fig 4. Quantitation of the globular / fibrillar actin ratio (G-actin / F-actin) in HUVEC following incubation
with 3 μM β-escin. A. Data shown were obtained in three independent experiments performed with cells from five
donors. The paired t-test (GraphPad Prism v.6.01) was used for statistical analysis. *p < 0.05. B. Typical assay
results showing changes in the amount of G-actin and F-actin in HUVEC treated with 3 μM β-escin. Abbreviations:
C—untreated HUVEC; E—β-escin treated cells.
doi:10.1371/journal.pone.0164365.g004
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Verification of iTRAQ results using the MRM technique
To verify the iTRAQ results we carried out MRM targetedMS analysis of selected proteins.
The advantage of MRM analysis includes higher specificity and detection accuracy combined
with the ability to process larger sample sets. The increased sample throughput allowed us to
analyze the effect of β-escin at 2 and 3 μM concentrations, with and without TNF-α, on
HUVEC obtained from six donors. The MRM analysis was composed of 32 proteins selected
from the iTRAQ-indicated pool of molecules with altered expression following β-escin and/or
TNF-α treatment (Table 1, Fig 6 and S3 Fig).
The MRM protein panel consisted of a selection of: 1) proteins that have been long recog-
nized as hallmarks of TNF-α activation of endothelial cells and are classically associated with
systemic inflammation such as SELE, ICAM1 and VCAM1 and potential novel endothelial
TNF-α-responsive proteins indicated by our global analysis, i.a. DNAJA1 and HHIP, 2) pro-
teins of the cholesterol biosynthesis and metabolism pathway and 3) proteins unaffected by
TNF-α but responding to β-escin.
1) β-escin influence on TNF-α responsive proteins. SID-MRM analysis confirmed
changes in abundance of 11 out of 15 TNF-α responsive proteins indicated by the iTRAQ anal-
ysis (Table 1 and S3 Fig). Importantly, SID-MRM analysis proved quantitative TNF-α
Fig 5. Top ten canonical pathways associated with β-escin action on HUVEC activated with TNF-α. The orange line represents the threshold p-
value (0.05). For pathways analysis proteins with significant alterations in quantity were submitted to Ingenuity Pathway Analysis. The taller are the bars
the more significant is the probability of association of proteins from the dataset with the canonical pathway.
doi:10.1371/journal.pone.0164365.g005
The Molecular Basis for Therapeutic Effectiveness of β-Escin
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dependent changes in the cellular content of three known TNF-α responders, TNFAIP2, CAT-
2 and COUP-TF1/COUP-TF2, for which p-values in the iTRAQ analysis did not reach statisti-
cal significance, i.e. the p-values were above 0.05 despite fold changes>1.3. Therefore, the
results of MRM analysis indicated that the iTRAQ-Diffprot cut-off value of p-value set in our
experiments at <0.05 was rather conservative, and validated our additional listing of proteins
in Tables A and B in S1 Methods with changes above 1.3-fold supported by four or more
peptides and with a Diffprot p-value>0.05 and<0.67. Moreover, SID-MRM analysis revealed
β-escin influence on six TNF-α-responsive proteins, which was not previously indicated by
the global iTRAQ analysis (S3 Fig), i.e. TNFAIP2, SOD2, CAT-2, DNAJA1, COUP-TF1/
COUP-TF2 and EHD1.
2) Cholesterol biosynthesis pathway. We performedMRM analysis also to validate the
biochemical data and results of the iTRAQ analysis which revealed a previously unknown,
Table 1. SID-MRM analysis of TNF-α and/or β-escin effect in HUVEC. For SID-MRM tests proteins were selected on the basis of iTRAQ indications.
Cells obtained from six different donors were used. Significant alternations according to Benjamini-Hochberg corrected p-values determined with t-test on
respective regression coefficients are indicated by asterisks (***—p value of 0.0001 to 0.001; **—0.001 to 0.01 and *—0.01 to 0.05; ns–non significant).




Change upon β-escin treatment
of TNF-α induced cells
affected by TNF-α Intercellular adhesion molecule 1 (ICAM-1 /
ICAM1)
" *** ns ns
Plasminogen activator inhibitor 1 (PAI-1 /
SERPINE1)
" *** ns ns
von Willebrand factor (vWF / VFW) # *** ns ns
Superoxide dismutase [Mn], mitochondrial
(SOD2)
" *** ns # *
Low affinity cationic amino acid transporter 2
(CAT-2 / SLC7A2)
" *** ns # *
Tumor necrosis factor alpha-induced protein 2
(TNFAIP2)
" *** ns # **
DnaJ homolog subfamily A member 1
(DNAJA1)
" ** ns # **
EH domain-containing protein 1 (EHD1) " * ns # *
COUP transcription factor 1 & 2 (COUP-TF1,
COUP-TF2 / NR2F1, NR2F2)
# ** # * ns
Thrombospondin-1 (THBS1) ns ns ns
affected by TNF-α
and β-escin
Vascular cell adhesion protein 1 (VCAM-1 /
VCAM1)
" *** ns # **
E-selectin (SELE) " *** ns ns
Endothelial protein C receptor (EPCR /
PROCR)
ns # * # **
Multimerin-1 (MMRN1) ns ns # *
Hedgehog-interacting protein (HHIP) ns ns ns
affected by β-escin Cathepsin B (CTSB) ns # ** # ***
Cathepsin Z (CTSZ) ns # ** # ***
Palmitoyl-protein thioesterase 1 (PPT-1 /
PPT1)
ns # * # ***
CD63 antigen (LAMP-3 / CD63) ns " ** " ***
Amyloid beta A4 protein (APP) ns " * " **
Integral membrane protein 2B (ITM2B) ns " ** " **
Matrix metalloproteinase-14 (MMP-14 /
MMP14)
ns " *** " **
Podocalyxin (PODXL) ns " * " **
doi:10.1371/journal.pone.0164365.t001
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potent up-regulation of the cholesterol biosynthesis pathway evoked with β-escin treatment
(Fig 6). The protein levels of seven biosynthetic enzymes (acetyl-CoA acetyltransferase/
ACAT2, hydroxymethylglutaryl-CoA synthase/HMGCS1, isopentenyl-diphosphate delta-
isomerase 1/IDI1, squalene synthase/FDFT1, delta(24)-sterol reductase/DHCR24, farnesyl
pyrophosphate synthase/FDPS and lanosterol synthase/LSS) and two molecules involved in
cholesterol transport (low-density lipoprotein receptor/LDLR and vigilin/HDLBP)were
evaluated. The results confirmed a clear stimulatory effect of β-escin on all the analyzed cho-
lesterol biosynthesis enzymes and LDLR in TNF-α stimulated cells. Although less pro-
nounced, the stimulatory effect of β-escin on enzymes involved in cholesterol biosynthesis
and transport was detected also in quiescent cells treated with the drug. The results support
the iTRAQ data, except for the transport-involved protein HDLBP, previously suggested to
be weakly decreased by β-escin-TNF-α treatment, now shown to be unaffected by any
treatments.
3) β-escin effect on non-TNF- α responding proteins. We performed SID-MRM analysis
also to verify changes in the profile of eight proteins not involved in cholesterol pathway which
appeared in the iTRAQ data to be β-escin and non-TNF-α responding (S3 Fig). The obtained
results confirmed a β-escin-evoked increase in the amount of APP, ITM2B, CD63, podocalyxin
and MMP-14 and a reduction in the abundance of cathepsin B, cathepsin Z and PPT-1 in β-
escin treated cells. For the latter group, TNF-α had a further reducing effect which was not
observedbefore in the iTRAQ analysis.
Fig 6. MRM analysis of proteins involved in the cholesterol biosynthesis pathway and transport. Relative protein amounts normalized to control
(with median and range) are derived from the geometric mean of signals for all peptides of a given protein. Significant differences between treatment
groups with a p -values <0.05, as determined using t- test with Benjamini -Hochberg correction are indicated.
doi:10.1371/journal.pone.0164365.g006
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β-escin dependent NFκB dysfunction
β-escin has been recently recognized as an inflammation attenuating agent, modulating the
TNF-α-mediated inflammatory pathways [13]. To investigate transcriptional events initiated
by HUVEC exposure to β-escin we measured the activity of NFκB, the master transcriptional
regulator of the inflammatory pathway. As shown in Fig 7, a decrease in TNFα-inducedNFκB
activation, illustrated by inhibition of nuclear translocation of p50 and p65, was detected in
cells treated with 3 μM β-escin.
Discussion
This study provides a thorough insight into the molecular and cellular mechanisms of the vas-
cular anti-inflammatory effect of β-escin.We show that this plant-based drug significantly
affects endothelial cell structure and function by disrupting the actin cytoskeleton and decreas-
ing expression of TNF-α—induced effector proteins. Our results suggest that the observed
effectsmay be linked to the β-escin induced disturbances of cholesterol homeostasis.
The ability of β-escin to interfere with cell membranes has been recognized as one of its
most characteristic features. In fact, a large number of biological effects of β-escin and other
saponins, has been ascribed to pore formation, release of cellular compounds and cell lysis. The
mechanism leading to perturbation of membrane integrity is not yet fully understood, but sev-
eral reports indicate the saponin-dependent loss of membrane cholesterol as a key event lead-
ing to cytotoxicity contributing to hemolytic activity of natural extracts with high saponin
content [19].
The current study verifiesmany of the commonly acknowledged β-escin toxicity concerns.
Although saponin induced cell damage and hemolysis have been considered as an important
obstacle in their clinical applications, we demonstrate that the pharmacological properties of β-
escin are not related to reduced endothelial cell viability. The thorough evaluation of β-escin
effect on HUVEC facilitated the proper estimation of non-toxic concentrations that appeared
to be significantly lower than in many of the previous studies [20].
Recently published data confirms that β-escin belongs to a group of potent membrane toxic
saponins inducing significantmembrane cholesterol release already after one hour of treatment
Fig 7. Effect of β-escin on NFκB p50 and p65 activation. Abbreviations: C—untreated cells; TNF—TNF-α-treated cells; E– 3 μM-
escin-treated cells. The results are expressed as the mean ±SEM of four independent experiments with HUVEC obtained from four
donors. Data were analyzed by one-way analyses of variance (ANOVA) followed by the post hoc Tukey multiple range test. *p < 0.05;
***p < 0.001
doi:10.1371/journal.pone.0164365.g007
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[19]. However, to the best of our knowledge, an augmented abundance of proteins involved in
cholesterol biosynthesis and increased cellular cholesterol content demonstrated in this study
have so far remained an unrecognized cellular effects of this drug. It could be speculated that
this phenomenon represents a strong compensatory response to β-escin-induced efflux of cel-
lular cholesterol, but a direct effect of the drug on cholesterol biosynthesis cannot be excluded.
Interestingly, an enhanced cholesterol biosynthesis following saponin treatment has been pre-
viously reported for one of the ginseng saponins, ginsenoside-Rb1 and a structure-function
relationship significant for exerting this effect has been proposed [21].
A large body of evidence points towards actin as one of the important links connecting cho-
lesterol to cytoskeleton organization and cellular function [22–24]. Therefore, β-escin induced
disturbances in cholesterol homeostasis could explain perturbations of actin cytoskeleton
integrity followed by rapid changes in cell functioning revealed in our analyses. As our proteo-
mic analysis indicated no influence of β-escin on actin synthesis, improper actin assembly
observed in β-escin treated cells could result from reduced expression of several well-studied
actin-associated proteins, including β-catenin, transgelin and tropomyosins TPM1 and TPM2.
An integral and functional actin cytoskeleton is recognized as a critical element in inflamma-
tory responses. Numerous studies showed that actin cytoskeleton disruption down-regulated
inflammatory events, including expression, production and secretion of inflammatorymedia-
tors, without affecting cell viability [25–27]. In endothelial cells exposed to pro-inflammatory
agonists, such as TNF-α or extracellular nucleotides, properly assembled actin cytoskeleton is
prerequisite for e.g. cell spreading, adhesion, migration and invasion [28–30]. It is also well
documented that actin plays a central role in regulating the width of the intercellular clefts in
endothelial cells, thereby controlling the paracellular pathway of vascular permeability [31].
Therefore, a defective actin organization in β-escin treated cells revealed in our study could be
considered as an important phenomenon underlying anti-inflammatory properties of this
drug. Interestingly, while down-regulatingmost of the analyzed proteins known to affect cellu-
lar functions through their association with actin cytoskeleton, β-escin increases the content of
podocalyxin.Functionally, this cell surface sialomucin acts as an anti-adhesin playing an
important role in cell migration, adhesion and lumen formation [32, 33]. However, recently
published data demonstrated a previously unrecognizedkey role of podocalyxin in the interac-
tions between endothelial cells and matrix that regulate vascular integrity [34]. Thus, β-escin—
mediated protection of endothelial layer integrity under inflammatory conditions demon-
strated in our study could be at least partially related to podocalyxin accumulation.
A β-escin—dependent decrease in the amount of multiple lysosomal molecules involved in
lipid metabolism, of which cathepsins constitute the most abundant group, appears as yet
another important element in the vascular anti-inflammatory β-escin action. The precise
mechanism by which β-escin could influence lysosomal fate is not known, but it has been
shown that both a decrease and an increase in cholesterol content may modulate lysosomal sta-
bility [35, 36]. The role of cathepsins in lipid degradation, and particularly in cholesterol efflux,
their involvement in inflammation, contribution to neovascularization and cardiovascular dis-
eases has been very well established [37, 38].
The perturbation of cholesterol content has also a significant impact on signal transduction.
The results of this study identify several signal transduction processes as relevant to β-escin
action, i.e. Tec kinase, PTEN, PI3K/Akt and actin cytoskeleton signaling.However, it is caveo-
lar mediated endocytosis signaling that has been classified as one of the canonical pathways
most significantly affected with β-escin treatment. This observation remains in concordance
with the established data recognizing signaling defects and an inhibition of endocytosis result-
ing from a disruption of caveolae as the major cholesterol-sensitive processes [39–41]. More
recently, another plausible mechanism of cholesterol dependent signaling dysregulation was
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suggested [42]. As cholesterol inserted between fatty acid acyl chains of biologicalmembranes
modulates their fluidity [43], it might affect the 3-D conformation and function of transmem-
brane proteins. A significant reduction in the nuclear translocation of NF-κB subunits in β-
escin treated cells stimulated with TNF-α presented in this study validates the data published
previously for significantly higher and, as shown in this study, β-escin concentrations toxic for
endothelial cells [44]. A blockade of NF-κB activation suggests a defect in TNF-α signaling
which could be linked either to inefficient TNF-α receptor function or to an disturbedNF-κB
translocation process. Both of the TNF-α receptors present in endothelial cells, TNFR1 and
TNFR2 contain only a single membrane-spanning domain and thus the conformational distur-
bances due to disturbedmembrane fluidity seem less probable. However, as the rates of actin
polymerization and depolymerization are critical determinants of NF-κB nuclear import and,
as a consequence, of transcriptional activity of NF-κB dependent genes [45], it is more proba-
ble that the observed reduction in nuclear transport of NF-κB subunits results from distur-
bances in actin arrangement rather than from TNF-α receptor dysfunction.
The results of proteomic analyses further strengthen the data on the detected inhibition of
the NF-κB pathway. A decreased content of TNF-α-induced effector proteins involved in dif-
ferent stages of endothelial cell activation, such as VCAM-1, TNFAIP2, CAT-2, SOD2, EHD1
and DNAJA1, detected in β-escin treated cells strongly suggests that β-escin acts as an inhibitor
of the TNF-α-regulated processes at the initial activation stage of the NF-κB pathway (see S4
Fig).
Interestingly, β-escin treatment has a profound influence also on proteins that are not
directly associated with any of the above mentioned pathways. Of particular importance seems
an increase in the content of two proteins playing a major role in the pathogenesis of Alzhei-
mer’s disease: APP, a direct precursor of β-amyloid, and ITM2B (BRI2), which is a physiologi-
cal suppressor of β-amyloid production [46]. This seemingly surprising result remains in
concordance with a constantly growing evidence reinforcing and extending the mechanistic
insight into cholesterol homeostasis and amyloidogenesis [47–51]. The identification of a β-
escin effect on amyloidogenesis could be considered particularly beneficial in the context of a
TNF-α related increase in amyloidogenic APP processing [52]. Depiction of the mechanism
underlying β-escin influence on APP processing and the potential role of the drug in preven-
tion and/or therapy of Alzheimer's diseasemerits more thorough studies.
The precise recognition of the role in β-escin exerted anti-inflammatory effects and other
cellular functions played by all the 75 β-escin-responsive proteins identified in the proteomic
analyses requires extended studies. Certain disturbances in the protein profile may represent
compensatory responses to disturbances in cholesterol content and actin depolimerization, as
discussed above and as it has been suggested for e.g. MMP14 (MT1-MMP) [53]. However, we
cannot exclude other underlyingmechanisms. Functional links between β-escin treatment and
the change in cellular content of other important for endothelial function, such as CD63, needs
to be established.
In summary, the global analysis of β-escin effects on endothelial cells suggests that the β-
escin induced perturbation in cholesterol homeostasis may be considered as the triggering
event in a cascade of cellular responses leading to cytoskeletal disarrangements followed by a
decreasedNFκB activation and down-expression of TNF-α—induced effector proteins. defin-
ing mechanisms of pharmacological effectiveness of the drug. Our results indicate that the vas-
cular anti-inflammatorymechanism of β-escin involves disturbances in cholesterol
homeostasis leading to cytoskeletal perturbations followed by decreasedNFκB activation.
Moreover, our data provide evidence for novel therapeutic potential of β-escin beyond current
vascular indications.
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Supporting Information
S1 Fig. Venn diagram showing the number of proteins exhibiting significant abundance
alterations as a result of the experimental treatments. Proteins with a q -value of<0.05, and
proteins with a fold change 1.3, identifiedwith 4 peptides and having a q value<0.67.
Abbreviations: Control–untreated cells; TNF–TNF-α-treated cells; E–cells treated with 3 μM
β-escin.
(TIF)
S2 Fig. The stimulatory effect of β-escin on cholesterol biosynthesis pathway observed in
TNF-α treated cells.The induced enzymes are marked in red.
(PDF)
S3 Fig. MRM analysis of proteins expressed differentially in TNF-α activatedHUVEC
treated with 3 μM β-escin.Relative protein amounts normalized to control (with median and
range) are derived from the geometricmean of signals for all peptides of a given protein as
indicated in Table B in S1 Methods. Significant differences between treatment groups with a p
-values<0.05, as determined using t- test with Benjamini -Hochberg correction are indicated.
(TIF)
S4 Fig. A summaryof the biological processes, pathways and proteins affected by β -escin
action. (Panel A) Arrow-ended lines indicate activation of a process or protein, blunt-ended lines
indicate inhibition and square-ended lines indicate both or an interaction. Up and down arrows
next to the proteins show significant changes in quantity observedas a result of TNF -α (black
arrows) and 3 μM β-escin (red arrows) in the iTRAQ and/orMRM analyses. Proteins measured
in our study are indicated in black with those in gray added for clarification of a pathway. Full pro-
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